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Abstract
Background: We report the case of a 6 year old boy suffering from adenohypophysis aplasia as well as ectopic
neurohypophysis and delayed diagnosis of familial Mediterranean fever (FMF).
Case presentation: The boy was diagnosed with panhypopituitarism during the neonatal period and suffered from
recurrent episodes during the following years suggesting infections. He also showed signs of adrenal insufficiency.
Finally, at the age of 6 years, an additional diagnosis of familial Mediterranean fever (FMF) was clinically suspected
and later confirmed by molecular analysis.
Conclusion: The clinical pictures of panhypopituitarism and FMF can be overlapping. It is imperative to take a
detailed and accurate history in order to find the right diagnosis, particularly a precise family history. In conditions
like FMF an early diagnosis is crucial, as initiation of treatment with colchicine is important to prevent long-term
complications due to amyloid fibril deposition.
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Background
Panhypopituitarism leads to growth hormone deficiency,
secondary hypogonadism (LH/FSH deficiency), hypothyr-
oidism (TSH deficiency) and adrenal insufficiency (ACTH
deficiency) [1]. Symptoms of adrenal insufficiency are not
specific and can mimic other processes. Patients with
an acute crisis of adrenal insufficiency generally
present with dehydration, hypotension, hypoglycemia,
or altered mental status. Symptoms of persistent ad-
renal insufficiency include chronic fatigue, anorexia,
nausea, vomiting, weight lcn [2].
Familial Mediterranean fever (FMF) is an auto-
somal recessive disorder that primarily affects
Sephardic Jewish, Armenian, Turkish and Arab pop-
ulations [3]. It is characterized by self-limited at-
tacks of fever and peritonitis, pleuritis or synovitis
recurring at irregular, unpredictable intervals and
lasting from 24 to 48 h. Clinical manifestations dur-
ing these attacks are mainly abdominal pain, chest
pain and arthritis but also myalgia, skin manifesta-
tions and scrotal swelling [4, 5].
We report the case of a boy who was diagnosed with
panhypopituitarism during the neonatal period and suf-
fered from recurrent episodes during the following years
suggesting infections while showing signs of adrenal
insufficiency. Finally, at the age of 6 years, the additional
diagnosis of familial Mediterranean fever (FMF) was
clinically suspected and confirmed later by molecular
analysis.
The clinical pictures of panhypopituitarism and FMF
are overlapping, thereby leading to delay in diagnosis
and suboptimal treatment if the underlying disorder is
recognized incorrectly.
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Case presentation
A 6-year-old male of Turkish origin had been treated since
birth because of adenohypophysis aplasia and ectopic
neurohypophysis resulting in panhypopituitarism with sec-
ondary adrenal insufficiency, hypothyroidism and growth
hormone deficiency. Due to persistent hypoglycemia, mus-
cular hypotonia, hyperbilirubinemia and unclear respiratory
and hemodynamic situations a cranial MRI (cMRI) had
been performed, showing an aplasia of the adenohypophy-
sis while the neurohypophysis presented as a punctiform
enhancement in the pituitary stalk. Laboratory markers of
the adrenal glands had been in concordance with the MRI
findings showing a blood plasma cortisol level of <0.5 μg/dl
and free cortisol <10 μg/24 h in urinalysis. ACTH level was
<5 pg/ml supporting the diagnosis of hypopituitarism.
Levels of Thyreoid-stimulating were <0.1 μIU/ml (0.35–4.5
μIU/ml), fT4 0.1 ng/dl (1.5–2.6 ng/dl), growth hormone
(GH) <0.05 ng/ml (random sample, 0.43–2.40 ng/ml),
Insulin-like growth factor binding protein 3 (IGFBP-3)
0.88 mg/l (0.80–3.60) and Insulin-like growth factor 1
(IGF-1) <25 ng/ml (41–313 ng/ml). Replacement treatment
was initiated with hydrocortisone, L-thyroxine and growth
hormone (Fig. 1).
However, beginning at the age of 2 years, recurrent epi-
sodes of abdominal pain, vomiting and raised temperature
were noticed. As no infectious causes could be detected
these episodes were attributed to the panhypopituitarism
and were followed by changes in treatment. During a
hospitalization for treatment optimization, the suspicion of
a second underlying disease was raised. While being admit-
ted the patient was suffering from relapsing episodes with
abdominal pain, vomiting, headache and fever (38–40 °C).
The parents later commented that the patient had been suf-
fering from similar episodes for about 4 years. Such epi-
sodes occurred suddenly twice a month lasting for 1 day.
While the attacks were interpreted as recurrent minor in-
fections and symptoms of secondary adrenal insufficiency,
hydrocortisone dosage was increased repeatedly. Despite
the increased dosage no clinical improvement was observed.
Clinical examination during those episodes showed a pale
boy in pain with diffuse moderate abdominal pain, normal
bowel sounds, and normal cardiopulmonary findings.
The following blood tests were normal during these
episodes: complete blood count, liver and renal function
tests and levels of ferritin and alpha-1-acid glycoprotein
(AGP). Erythrocyte sedimentation rate (ESR) was
70 mm/h [normal value: <10 mm/h]. Furthermore infec-
tious causes were excluded as all tests were normal,
namely urine tests, stool microbiology and virology, and
calprotectin in the stool.
There was no indication of chronic inflammatory bowel
disease; however, the parents reported a female cousin of
the patient who had been suffering from relapsing abdom-
inal pain, joint pain and fever since the age of 6 years.
Since the parents were consanguineous the clinical suspi-
cion of familial Mediterranean fever was raised.
Laboratory diagnostics showed serum amyloid A (SAA)
remarkably elevated at 1180 mg/l [normal value: <10 mg/l].
Molecular genetic testing revealed a homozygous M694V
mutation of the MEFV gene (p.Met694Val, c.2080A>G),
confirming the diagnosis of familial Mediterranean fever.
Therapy with colchicine was started at a dose of 1 mg per
day. Within 3 weeks SAA decreased to 4.20 mg/l and nei-
ther fever nor abdominal pain have occurred again within 6
months. During long-term follow-up the patient was not
admitted again due to abdominal pain or episodes of
recurrent fever; on long-term follow-up severity of
symptoms was mild under colchicine treatment. Hormonal
substitution was adjusted repeatedly for weight and clinical
needs, and an interaction of both treatment regimens was
not observed.
Conclusions
As different endocrinological axes in panhypopituitarism
are impaired, clinical symptoms vary and are not specific
[1]. Adrenal insufficiency is the main cause of morbidity;
the most dangerous complications are adrenal crises,
which occur if cortisol levels do not meet the body’s
acute demand [5], possibly leading to hypovolemic shock
due to increased vascular permeability. Hence, acute
Fig. 1 T1 sagittal MRI. Adenohypophysis is morphologically not
definable, therefore, aplasia is suspected. The neurohypophysis presents
as punctuate signal enhancement midsize of the hypophysis stem
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adrenal insufficiency can present itself with symptoms
such as acute dehydration, hypotension or hypoglycemia.
The treatment goal, therefore, is achieving a homeostasis
in the endocrinological axes, which is mainly substitu-
tional. Adjustment of the glucocorticoid dosage is essen-
tial, especially during episodes of stress [6], such as
infection, surgery, or major trauma.
Familial Mediterranean fever (FMF) is one the most com-
mon auto-inflammatory diseases characterized by recurrent
episodes of polyserositis and fever, also known as familial
paroxysomal polyserositis or recurrent hereditary polysero-
sitis [7]. It is thought to be gene-associated as an autosomal
recessive trait. Lately, doubts have been raised as cases of
patients suffering from FMF with heterozygous status have
been reported [8]. While the etiology is still uncertain, it is
seen primarily in certain ethnic groups, such as Sephardic
Jewish, Armenian, Turkish and Arab populations [5], al-
though there have been reports of large cohorts in different
populations, e.g. from Japan [9]. Affected pediatric patients
present with heterogeneous symptoms. In a study by
Majeed et al., more than 400 pediatric patients presented
with abdominal pain in 81 % of exacerbations, chest pain
(41 %), arthritis (42 %), severe myalgia (11 %), erysipelas-
like skin manifestation (12 %), scrotal swelling (4 %), and
recurrent episodic fever (3 %) [5]. Generally, during acute
attacks serum markers of systemic inflammation are raised,
and elevation of SAA is typical.
Diagnostic criteria include: (i) typical clinical manifesta-
tions, (ii) positive response to colchicine and (iii) genetic
testing. FMF may subsequently be complicated by AA
amyloidosis leading to chronic renal failure [10], which oc-
curs in approximately 30 % of Sephardic Jews and 60 % of
Turks with FMF [11]. The standard treatment for prevent-
ing attacks and amyloid deposition in patients with FMF is
daily treatment with colchicine, reducing morbidity, par-
ticularly proteinuria, remarkably [12, 13]. Although the
precise mechanism of colchicine in FMF treatment re-
mains unknown, its beneficial role in treatment to induce
remission has been substantiated in various studies. It
should be introduced as soon as the diagnosis of FMF has
been established and be continued for life. It has been re-
ported to be beneficial even when amyloidosis is already
present [12]. Alternative treatments for non-responders
(approximately 5 %) are scarce; few studies have been con-
ducted up to now. An anti-IL-1 treatment seems to be
beneficial and studies showed the efficacy of Anakinra and
Canakinumab in pediatric patients with FMF or juvenile
idiopathic arthritis [14, 15].
FMF and symptoms secondary to panhypopituitarism
are overlapping and characterized by rather non-specific
symptoms (Table 1). In a study of 60 adult patients with
adrenal insufficiency, the main causes of adrenal crises
were gastrointestinal infection and fever [6]. Our patient
presented repeatedly with abdominal pain, vomiting and
headache. These symptoms were misinterpreted as recur-
rent minor infections for several years, resulting in an
adrenal crisis.
One of the most helpful approaches in diagnosis is
taking a detailed history. The Turkish origin of this pa-
tient, his parents’ consanguinity, and similar symptoms
of the female cousin without panhypopituitarism finally
led to the suspected diagnosis of FMF, which was con-
firmed by high levels of serum amyloid A and molecular
genetic testing.
To our knowledge panhypopituitarism and FMF in the
same pediatric patient have not been described before.
Cases of hypoadrenal syndrome in patients with FMF have
been described, mainly due to amyloid fibril deposition in
adrenal glands [4]. Kadayifci et al. reported the coexistence
of FMF and Addison’s disease in a young woman, suppos-
ing a similar immune mechanism of both diseases, suggest-
ing a decreased suppressor T-cell-function, as seen in FMF
and being a major disturbance in cellular immunity in Ad-
dison patients [4]. In our patient panhypopituitarism had
been diagnosed already during the neonatal period. Due to
persistent hypoglycemia, muscular hypotonia, hyperbiliru-
binemia and unclear respiratory and hemodynamic situa-
tions, a cMRI had been performed, showing aplasia of the
adenohypophysis. Laboratory markers of the adrenal glands
had been in concordance with the MRI findings. The diag-
nosis of FMF could be clinically and genetically confirmed;
a single cause of both conditions is highly unlikely, as is an
underlying immune mechanism.
Overlapping clinical signs and symptoms of infection, ad-
renal insufficiency, as well as systemic inflammation, can
delay diagnosis of autoimmune disorders such as FMF. In
any case a detailed anamnesis is crucial, especially an accur-
ate family history, which should be one of the focal points
of every investigation.
Attacks should be prevented, particularly in patients
with adrenal insufficiency, as they can be stressors
Table 1 Symptoms of adrenal insufficiency and familial
Mediterranean fever
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triggering adrenal crises leading to further complica-
tions. Early diagnosis is important to avoid unnecessary
and invasive diagnostics such as laparotomy or append-
ectomy. In addition, early diagnosis may prevent long-
term complications such as amyloidosis, and colchicine
treatment should be initiated as soon as possible.
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